Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: Correlation with clinicopathological parameters

Histology and Histopathology

Volumn 22, Issue 1-3, 2007, Pages 305-309

  Jin, J S ^a   Cheng, T F ^b   Tsai, W C ^a   Sheu, L F ^a   Chiang, H ^c   Yu, Cheng Ping ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b Shin Kong Wu Ho Su Hospital   (Taiwan)

^c Taipei Institute of Pathology   (Taiwan)

Author keywords

Ductal carcinoma in situ; Fibroadenoma; Invasive ductal carcinoma; Serine protease matriptase

Indexed keywords

MATRIPTASE; SERINE PROTEINASE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST FIBROADENOMA; CANCER GRADING; CANCER STAGING; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE MICROARRAY;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHINA; FEMALE; FIBROADENOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; SERINE ENDOPEPTIDASES; TAIWAN; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33846325108     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Anagnostopoulos I., Anagnostopoulos C., Vergados D., Rouskas A. and Kormentzas G. (2006) The Wisconsin breast cancer problem: Diagnosis and TTR/DFS time prognosis using probabilistic and generalised regression information classifiers. Oncol. Rep. 15, 975-981.
2. Benaud C.M., Oberst M., Dickson R.B. and Lin C.Y. (2002) Deregulated activation of matriptase in breast cancer cells. Clin. Exp. Metastasis 19, 639-649.
3. Bhatt A.S., Takeuchi T., Ylstra B., Ginzinger D., Albertson D., Shuman M.A. and Craik C.S. (2003) Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. Biol. Chem. 384, 257-266.
4. Duffy M.J. (1992) The role of proteolytic enzymes in cancer invasion and metastasis. Clin. Exp. Metastasis 10, 145-155.
5. Ellis I.O., Galea M.H., Locker A., Roebuck E.J., Elston C.W., Blamey R.W. and Wilson A.R.M. (1993) Early experience in breast cancer screening: emphasis on development of protocols for triple assessment. Breast 2, 148-153.
6. Jaaback K.S., Ludeman L., Clayton N.L. and Hirschowitz L. (2006) Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period. Int. J. Gynecol. Cancer 16, 123-128.
7. Jin J.S., Chen A., Hsieh D.S., Yao C.W., Cheng M.F. and Lin Y.F. (2006a) Expression of Serine Protease Matriptase in Renal Cell Carcinoma. Int. J. Surg. Pathol. 14, 65-72.
8. Jin J.S., Hsieh D.S., Loh S.H., Chen A., Yao C.W. and Yen C.Y. (2006b) Increasing Expression of Serine Protease Matriptase in ovary tumors: Tissue Microarray Analysis of Immunostaining Score with Clinicopathological Parameters. Mod. Pathol. 19, 447-452.
9. Jin J.S., Hsieh D.S., Lin Y.F., Wang J.Y., Sheu L.F. and Lee W.H. (2006c) Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: Tissue microarray analysis of immunostaining score with clinicopathological parameters. Int. J. Urol. 13, 571-578.
10. Jin J.S., Yao C.W., Loh S.H., Cheng M.F., Hsieh D.S. and Bai C.Y. (2006d) Increasing expression of extracellular matrix metalloprotease inducer in ovary tumors: Tissue microarray analysis of immunostaining score with clinicopathological parameters. Int. J. Gynecol. Pathol. 25, 140-146.
11. Kuroi K., Toi M., Tsuda H., Kurosumi M. and Akiyama F. (2006) Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer 13, 38-48.
12. Lam J.S., Belldegrun A.S. and Figlin R.A. (2004) Tissue array-based predictions of pathobiology, prognosis and response to treatment for renal cell carcinoma therapy. Clin. Cancer Res. 10, 6304s-6309S.
13. Lin C.Y., Anders J., Johnson M., Sang Q.A. and Dickson R.B. (1999) Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J. Biol. Chem. 274, 18231-18236.
14. Lin C.Y., Wang J.K., Torri J., Dou L., Sang Q.A. and Dickson R.B. (1997) Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J. Biol. Chem. 272, 9147-9152.
15. Liotta L.A., Steeg P.S. and Stetler-Stevenson W.G. (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327-336.
16. Oberst M., Anders J., Xie B., Singh B., Ossandon M., Johnson M., Dickson R.B. and Lin C.Y. (2001) Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am. J. Pathol. 158, 1301-1311.
17. Oberst M.D., Johnson M.D., Dickson R.B., Lin C.Y., Singh B., Stewart M., Williams A., al-Nafussi A., Smyth J.F. and Gabra H. (2002) Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer. Correlation with clinical outcome and tumor clinicopathological parameters. Clin. Cancer Res. 8, 1101-1107.
18. Shi Y.E., Torri J., Yieh L., Wellstein A., Lippman M.E. and Dickson R.B. (1993) Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res. 53, 1409-1415.
19. Tanimoto H., Underwood L.J., Wang Y., Shigemasa K., Parmley T.H. and O'Brien T.J. (2001) Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol. 22, 104-114.
20. Tryggvason K., Hoyhtya M. and Salo T. (1987) Proteolytic degradation of extracellular matrix in tumor invasion. Biochem. Biophys. Acta 907, 191-207.
21. Yamashita H., Yando Y., Nishio M., Zhang Z., Hamaguchi M., Mita K., Kobayashi S., Fujii Y. and Iwase H. (2006) Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.Breast Cancer. 13, 74-83.
22. Zhang Y., Cai X., Schlegelberger B. and Zheng S. (1998) Assignment of human putative tumor suppressor genes ST13 (alias SNC6) and ST14 (alias SNC19) to human chromosome bands 22q13 and 11q24 q25 by in situ hybridization. Cytogenet. Cell Genet. 83, 56-57.